Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

AstraZeneca has picked off another label expansion for its cancer blockbuster Imfinzi (durvalumab) as the FDA has ...

AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended by NICE for treating adults with ...

The FDA approves AZN's Imfinzi for treating patients with limited-stage small-cell lung cancer based on phase III ADRIATIC ...

AstraZeneca's Imfinzi gains FDA Priority Review for bladder cancer. Key trial data shows improved survival and progression ...

AstraZeneca’s IMFINZI® (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following ...

The U.S. Food and Drug Administration has approved AstraZeneca blockbuster drug Imfinzi to treat some adults with ...

AstraZeneca AZN announced that the FDA has accepted and granted priority review to its supplemental biologics license ...

FDA 已授予阿斯利康 Imfinzi (durvalumab) 补充生物制品许可申请 (sBLA) 优先审查资格，该申请用于治疗肌层浸润性膀胱癌 (MIBC)。据该公司称，sBLA 得到了 III 期 NIAGARA ...

Imfinzi is already approved for extensive-stage SCLC based on the results of the CASPIAN trial, as well as for locally ...

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has ...

Cambridge: AstraZeneca's supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab) has been accepted and ...